Working… Menu

Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis (ACE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02579733
Recruitment Status : Terminated (Not enough number of enrolling patient)
First Posted : October 20, 2015
Last Update Posted : August 14, 2019
Information provided by (Responsible Party):
Eun Soo Kim, MD, PhD, Kyungpook National University

Brief Summary:
The aim of this study is to determine whether azathioprine is effective for mucosal healing in UC patients who achieved clinical remission by the first course of corticosteroids but not mucosal healing in endoscopy.

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Drug: Azathioprine Drug: Placebo Phase 4

Detailed Description:

The sample size was calculated based on the previous study showing the difference of mucosal healing rate between azathioprine (58%) and 5-aminosalicylate (21%). With a two-tailed test of α = 0.05 and 1 - ß = 0.8, 52 patients were required.

The placebo drug which is identical to azathioprine will be provided by Celltrion drug company.

Differences in the categorical variables between the groups are examined with χ2 or the Fisher exact test. For comparisons of continuous variables, a Student t test is used.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : February 1, 2016
Actual Primary Completion Date : December 1, 2018
Actual Study Completion Date : December 1, 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Azathioprine
Azathioprine (1.5mg/kg) po for 1 year
Drug: Azathioprine
Placebo Comparator: Sugar pill
Placebo drug identical to azathioprine (1.5mg/kg) po for 1 year
Drug: Placebo

Primary Outcome Measures :
  1. Mucosal healing status [ Time Frame: one year ]
    Mucosal healing status will be assessed by sigmoidoscopy using Mayo endoscopic score.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ulcerative colitis patients with moderate to severe activity who achieved a clinical remission by the first course of corticosteroids
  • Newly diagnosed or without steroid use during last 1 year
  • Endoscopic Mayo subscore >0

Exclusion Criteria:

  • Patients with azathioprine or biologics therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02579733

Layout table for location information
Korea, Republic of
Kyungpook National University Hospital
Daegu, Korea, Republic of, 41944
Sponsors and Collaborators
Kyungpook National University
Layout table for investigator information
Principal Investigator: Eun Soo Kim, MD, PhD Kyungpook National University

Layout table for additonal information
Responsible Party: Eun Soo Kim, MD, PhD, Professor, Kyungpook National University Identifier: NCT02579733     History of Changes
Other Study ID Numbers: KMU-151016
First Posted: October 20, 2015    Key Record Dates
Last Update Posted: August 14, 2019
Last Verified: August 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents